Letters to the Editor

A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia

Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
Division of Hematology/Oncology, Northwestern University, Chicago, Illinois
Washington University School of Medicine, Siteman Cancer Center, St Louis, MO
Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Department of Pathology, The Ohio State University, Columbus, OH
Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riß
Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riß
Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT
Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT
Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA
Haematologica Early view Dec 2, 2021 https://doi.org/10.3324/haematol.2020.274118